Does Insulin Resistance Increase the Probability of Fibrocystic Breast Disease in Women with Polycystic Ovary Syndrome

Yıl 2023, Cilt: 40 Sayı: 4, 692 - 696, 03.01.2024

Selçuk Öktemer Ayşe Şeyma Küçükakça

Öz

The aim of this study was to investigate if higher insulin resistance (IR) levels among polycystic ovary syndrome (PCOS) patients are the predictor of the fibrocystic breast disease risk in women aged 30-40 years. This case-control retrospective observational study was carried out on 180 patients admitted between September 2020 and June 2022. Women aged 18-36 years diagnosed with PCOS included the study. Women who were diagnosed with PCOS but not fibrocystic breasts formed the control group. Women were divided according to their IR levels into four groups. The optimal insulin (23.6% vs. 54.65), the insulin sensitivity (22.7% vs. 28.6), early IR (29.1% vs. 18.6), and significant IR (24.5% vs. 25.7) were similar between women with fibrocystic breasts and normal breasts, respectively. This study showed no statistically significant difference between women with fibrocystic breasts and normal breasts in study parameters (p-value > 0.05). There was no statistically difference between two groups in terms of IR levels. The results show that IR levels cannot be used to assess fibrocystic breast disease in PCOS women.

Anahtar Kelimeler

Insulin resistance, polycystic ovarian syndrome, benign breast disease, fibrocystic breast changes

Kaynakça

• 1. Gurbuz T, Alanya Tosun S, Cebi A, Gokmen O, Usta M. Investigating Fetuin-A and Paraoxonase-1 Activity as Markers in Polycystic Ovary Syndrome Based on Body Mass Index: A Prospective Case-Control Study. Cureus 2021; 13: 18553.
• 2. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7.
• 3. Dokuzeylül Güngör N, Güngör K, Celik N, Önal M, Madenli AA. Impact of body mass index and vitamin D on serum AMH levels and antral follicle count in PCOS. Eur Rev Med Pharmacol Sci 2023; 27: 179-87.
• 4. Mayer SB, Evans WS, Nestler JE. Polycystic ovary syndrome and insulin: our understanding in the past, present and future. Womens Health 2015; 11: 137-49.
• 5. Alanya Tosun Ş, Gurbuz T, Cebi A, Tosun A, Gokmen O, Usta M. Association of increased levels of omentin-1 and carotid intima-media thickness with early signs of cardiovascular risk in patients with polycystic ovary syndrome: A prospective case control study. J Obstet Gynaecol Res 2022; 48: 169-77.
• 6. Madenli AA, İnci Ö, Gürbüz T. The relationship between anti mullerian hormone level and endometrial polyp frequency in patients with polycystic ovary syndrome. JOMPAC 2022; 3: 263-7.
• 7. Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World J Diabetes 2022; 13: 129-49.
• 8. Bannigida DM, Nayak BS, Vijayaraghavan R. Insulin resistance and oxidative marker in women with PCOS. Arch Physiol Biochem 2020; 126: 183-6.
• 9. Muscogiuri G, Barrea L, Caprio M, et al. Nutritional guidelines for the management of insulin resistance. Crit Rev Food Sci Nutr 2022; 62: 6947-60.
• 10. Kohnepoushi P, Dehghanbanadaki H, Mohammadzedeh P, Nikouei M, Moradi Y. The effect of the polycystic ovary syndrome and hypothyroidism on the risk of fibrocystic breast changes: a meta-analysis. Cancer Cell Int 2022; 22: 125.
• 11. Güngör ND, Gürbüz T, Okçu NT. Correlation between HbA1c and fibrocystic breast disease among polycystic ovary syndrome. Cumhuriyet Med J 2020; 42: 383-9.
• 12. Kunicki M, Smolarczyk R. Polycystic Ovary Syndrome and Fibrocystic Breast Disease: An Updated Review. Horm Metab Res 2021; 53: 219-24.
• 13. Chen YY, Fang WH, Wang CC, et al. Examining the Associations among Fibrocystic Breast Change, Total Lean Mass, and Percent Body Fat. Sci Rep 2018; 8: 9180.
• 14. Soran A, Talbott EO, Zborowski JV, Wilson JW. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract 2005; 59: 795-7.
• 15. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005; 353: 229-37.
• 16. Castellano I, Metovic J. Fibrocystic Breast Changes. Breast Pathology: Springer. 2019; 110-6.
• 17. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149-60.
• 18. Weaver M, Stuckey A. Benign Breast Disorders. Obstet Gynecol Clin North Am 2022; 49: 57-72.
• 19. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers 2021; 13: 4287.
• 20. Burrows C, Holly JM, Laurence NJ, et al. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 2006; 147: 3484-500.
• 21. Santen RJ. Benign Breast Disease in Women. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc. 2018.
• 22. Samoli E, Trichopoulos D, Lagiou A, et al. The hormonal profile of benign breast disease. Br J Cancer 2013; 108: 199-204.
• 23. D'Amelio R, Farris M, Grande S, Feraudo E, Iuliano A, Zichella L. Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest 2001; 51: 134-7.
• 24. Gumus II, Koktener A, Dogan D, Turhan NO. Polycystic ovary syndrome and fibrocystic breast disease: is there any association?. Arch Gynecol Obstet 2009; 280: 249-53.
• 25. Eslami B, Alipour S, Hosseini R, Fattah B, Moini A. Breast density in polycystic ovarian syndrome patients: A case-control study. Int J Reprod Biomed 2019; 17: 577-84.
• 26. Sarac ZF, Bilgen I. Association between insulin resistance and breast parenchyma in women with polycystic ovary syndrome/Polikistik Over Sendromlu Kadnlarda insulin Direnci ve Meme Paterni Arasndaki iliski. Turkjem 2012; 16: 1-6.
• 27. Gouveri E, Papanas N, Maltezos E. The female breast and diabetes. Breast 2011; 20: 205-11.
• 28. Ye F, Wen J, Yang A, et al. The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis. Clin Breast Cancer 2022; 22: 48-58.
• 29. Guzik P, Gęca T, Topolewski P, et al. Diabetic Mastopathy. Review of Diagnostic Methods and Therapeutic Options. Int J Environ Res Public Health 2021; 19: 448.
• 30. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-62.
• 31. Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: a meta-analysis. Endocr Relat Cancer 2012; 19: 793-803.
• 32. Wang XL, Jia CX, Liu LY, Zhang Q, Li YY, Li L. Obesity, diabetes mellitus, and the risk of female breast cancer in Eastern China. World J Surg Oncol 2013; 11: 71.
• 33. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health 2013; 25: 368-87.
• 34. Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012; 107: 1608-17.